Editas Medicine Profile

<div class='circular--portrait' style='background:#8A0CCF;color: white;font-size:3em;padding-top: 25px;;'>EDI</div>


13 / 100

Odds of Distress

Analyze Filter   Earning Report: February 27, 2020
Equity ratings for Editas Medicine are calculated based on Macroaxis scoring framework. The performance scores are derived for the period starting October 22, 2019 and ending today January 20, 2020. Click here to learn more.

Editas Medicine Profile

Upcoming quarterly earning report is expected on February 27, 2020. Editas Medicine, Inc. operates as a clinical stage genome editing company. Editas Medicine, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts. Editas Medicine operates under Biotechnology classification in USA and is traded on BATS Exchange. It employs 133 people. more on Editas Medicine
Editas Medicine Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
Editas Medicine SEC Filings
Editas Medicine SEC Filings
Security & Exchange Commission EDGAR ReportsView All
Legal NameEditas Medicine
President CEO, DirectorKatrine BosleyView All
Thematic Classification
Currently Active Investing Idea
  Pharmaceutical Products
View All
Average Analyst Recommendation
Current trade recommendation based on an ongoing consensus estimate among financial analysis covering Editas Medicine.
Piotroski F Score
Academic score to determine the current strength of Editas Medicine financial position
Macroaxis Advice
Macroaxis buy hold or sell recommendation provided in the context of your current investment horizon and risk tolerance.
Financial Strength
Editas Medicine ability to generate sufficient cash flow to pay bills, repay debt, and make consistent year-to-year profit
Total Debt
Debt Current
Debt Non Current
Long Term Debt to Equity
Debt to Equity Ratio
Return on Investment
Return on Average Assets
Return on Average Equity
Return on Invested Capital
Return on Sales
Earnings per Basic Share
Earnings per Diluted Share
Price to Earnings Ratio
Earnings before Tax
Few selected profitability drivers of Editas Medicine representing accounts that assess its ability to generate profits relative to its revenue, operating costs, and shareholders' equity
Consolidated Income
Net Income
Net Income Common Stock
Operating Income
Net Income Per Employee
Gross Margin
Profit Margin
Editas Medicine (EDIT) is traded on BATS Exchange in USA. It is located in 11 Hurley Street, Cambridge, MA 02141, United States and employs 133 people. Editas Medicine is listed under Pharmaceutical Products category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with current market capitalization of 1.02 B. Editas Medicine conducts business under Healthcare sector and is part of Biotechnology industry. The entity has 49.52 M outstanding shares of which 8.73 M shares are currently shorted by private and institutional investors with about 9.04 trading days to cover. EDIT currently holds about 317.93 M in cash with (61.32 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.5.
Check Editas Medicine Probability Of Bankruptcy

Ownership Allocation (%)

Editas Medicine Target Price Odds Analysis

Odds Below 29.26HorizonTargetOdds Above 29.26
70.18%30 days 29.26 29.72%
Based on normal probability distribution, the odds of Editas Medicine to move above current price in 30 days from now is about 29.72 (This Editas Medicine probability density function shows the probability of Editas Medicine Stock to fall within a particular range of prices over 30 days) .

Editas Medicine Top Holders

Editas Medicine Income Statement Over Time

Consolidated Income    Earning Before Interest and Taxes EBIT    Net Income    

Editas Medicine Against Markets

Did you try this?

Run Performance Analysis Now


Performance Analysis

Check effects of mean-variance optimization against your current asset allocation
All  Next Launch Module

Editas Medicine Upcoming and Recent Events

Editas Medicine Company Earnings Announcements Dates

Upcoming Quarterly Earning ReportFebruary 27, 2020
Next Earnings ReportMay 5, 2020
Next Fiscal Quarter EndDecember 31, 2019
Next Fiscal Year EndFebruary 27, 2020
Last Quarter Report DateSeptember 30, 2019
Last Earning Anouncement DateDecember 31, 2018

Editas Medicine Corporate Filings

Editas Medicine SEC Reporting

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Financial Statements and Exhibits. Results of Operations and Financial Condition
Unclassified Corporate Event
Entry into a Material Definitive Agreement

Editas Medicine Corporate Directors

Kevin Bitterman Independent Director
John Mendlein Independent Director
Boris Nikolic Independent Director
Continue to Investing Opportunities. Please also try Headlines Timeline module to stay connected to all market stories and filter out noise. drill down to analyze hype elasticity.
Company logos by clearbit